A landmark study in Lancet Diabetes & Endocrinology identified a T1D subtype in Sub-Saharan African youth and Black Americans lacking islet autoantibodies. This insulin-deficient form isn't autoimmune, urging revised diagnostic, prevention, and treatment strategies.
Did you know? A randomized crossover trial published in August 2025 demonstrated that a DASH diet modified for type 2 diabetes (DASH4D) significantly improved glycemic control. Adults with T2D on the DASH4D regimen experienced greater reductions in mean CGM glucose and increased time in the target range compared to standard U.S. dietary patterns. Improvements were most pronounced in participants with elevated baseline A1C.
Could evidence-based dietary frameworks like DASH4D enhance existing treatment plans for patients with complex metabolic profiles?
Could evidence-based dietary frameworks like DASH4D enhance existing treatment plans for patients with complex metabolic profiles?
Source : https://pubmed.ncbi.nlm.nih.gov/39838543/
A targeted and structured approach to the detection and treatment of sarcopenia and sarcopenic obesity can make a major contribution to the maintenance or improvement of these patients' functionality and...
Sarcopenia and sarcopenic obesity impair function, increase risks, and affect quality of life in aging populations. Early screening, resistance training, and nutritional interventions are essential for prevention and management.
I use clinical factors based on the approved indications to minimize coverage hassles. Long-term adherence is generally good if there is good tolerance and efficacy. These are truly miracle drugs for many.
getting coverage is the main challenge in my area, pts are open to start weight loss medications but they cannot afford it and oral medications give only minimal weight loss. many pts do not realize that weight loss medications are frequently taken for life and they nod need to exercise and follow a well balanced diet so they can achieve the best...